PRO-RIVAROXABAN 2.5 MG
RIVAROXABAN : 2.5 MG · DIN 02540967 · PRO DOC LIMITEE
Health Canada status: MARKETED
What is PRO-RIVAROXABAN?
PRO-RIVAROXABAN 2.5 MG contains RIVAROXABAN : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02540967, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Nov-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRO-RIVAROXABAN used for?
PRO-RIVAROXABAN (rivaroxaban) film-coated tablet (10 mg, 15 mg, 20 mg) is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery; treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE; prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate. PRO-RIVAROXABAN (rivaroxaban) film-coated tablet (2.5 mg), in combination with 75 mg – 100 mg acetylsalicylic acid (ASA), is indicated for the prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD); prevention of atherothrombotic events in patients with symptomatic PAD at demonstrated high risk of major adverse limb events (MALE) or major adverse cardiovascular and cerebrovascular events (MACCE). PRO-RIVAROXABAN (rivaroxaban) film-coated tablet (15 mg) is indicated for the treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. PRO-RIVAROXABAN (rivaroxaban) film-coated tablet (20 mg) is indicated for the treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02540967 |
|---|---|
| Brand name | PRO-RIVAROXABAN |
| Generic / active ingredient | RIVAROXABAN : 2.5 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AF01 RIVAROXABAN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Nov-2023 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code B01AF01 RIVAROXABAN. 68 of 97 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-RIVAROXABAN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02527995 |
| AG-RIVAROXABAN | 15 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528002 |
| AG-RIVAROXABAN | 2.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02555255 |
| AG-RIVAROXABAN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528010 |
| APO-RIVAROXABAN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02470497 |
| APO-RIVAROXABAN | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02470500 |
| APO-RIVAROXABAN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02541734 |
| APO-RIVAROXABAN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02470519 |
| AURO-RIVAROXABAN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560356 |
| AURO-RIVAROXABAN | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560364 |
Who else supplies RIVAROXABAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIVAROXABAN appears in 2966 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.